Do Remeron (mirtazapine) and Rexulti (brexpiprazole) affect liver function in patients, particularly those with pre-existing liver conditions?

Hepatic Effects of Remeron (Mirtazapine) and Rexulti (Brexpiprazole)

Both Remeron (mirtazapine) and Rexulti (brexpiprazole) can affect the liver, with mirtazapine carrying documented risk of hepatotoxicity including rare cases of prolonged jaundice, while brexpiprazole requires dose reduction in moderate-to-severe hepatic impairment due to increased drug exposure.

Mirtazapine (Remeron) Hepatic Effects

Direct Hepatotoxicity Risk

• Mirtazapine is substantially excreted by the kidney (75%), but its clearance is reduced in patients with hepatic impairment, leading to increased plasma levels 1
• Case reports document severe hepatotoxicity with mirtazapine, including prolonged jaundice lasting up to 3 months after drug withdrawal 2
• Granulocytopenia and elevated alanine aminotransferase levels have been reported, though most are mild and may resolve with continued administration 3

Dosing in Hepatic Impairment

• Dose reduction is necessary when administering mirtazapine to patients with moderate to severe hepatic impairment 1
• The FDA label specifically warns that plasma mirtazapine levels may be increased in patients with hepatic impairment compared to those without 1

Monitoring Requirements

• While routine liver function monitoring is not mandated by the FDA label for patients with normal baseline hepatic function, patients with pre-existing liver disease require careful clinical and laboratory monitoring 1
• Based on general principles for hepatotoxic medications, patients should be educated about symptoms of liver injury (fever, malaise, vomiting, jaundice) and instructed to stop medication and seek immediate evaluation if these occur 4

Brexpiprazole (Rexulti) Hepatic Effects

Dose Adjustments Required

• The maximum recommended dosage in patients with moderate to severe hepatic impairment (Child-Pugh score ≥7) is lower than in those with normal hepatic function 5
• Patients with moderate to severe hepatic impairment have higher exposure to brexpiprazole than those with normal hepatic function, which increases the risk of adverse reactions 5

Clinical Implications

• Unlike mirtazapine, brexpiprazole does not have documented cases of direct hepatotoxicity in the provided evidence
• The primary concern is pharmacokinetic—reduced hepatic clearance leads to drug accumulation rather than direct liver injury 5
• Brexpiprazole is highly protein-bound, making it unlikely that hemodialysis would be beneficial in overdose situations 5

Practical Management Algorithm

For Patients with Normal Baseline Liver Function

1. Obtain baseline liver function tests (AST, ALT, alkaline phosphatase, bilirubin) before initiating either medication 6
2. Educate patients about symptoms requiring immediate drug cessation: fever, malaise, vomiting, jaundice, unexplained deterioration 4
3. Do not perform routine monitoring if baseline tests are normal, but repeat immediately if symptoms develop 4

For Patients with Pre-existing Liver Disease

1. Screen for hepatitis B and C in high-risk patients (injection drug users, those from endemic regions, HIV-positive) 6
2. If baseline ALT is 2-5× upper limit of normal: monitor weekly for 2 weeks, then every 2 weeks until normalized 4
3. If baseline ALT >3× upper limit of normal: reduce mirtazapine dose and consider alternative to brexpiprazole or use reduced dosing 6, 5
4. If ALT rises to 5× normal or bilirubin rises at any time: immediately discontinue the offending medication 4

Critical Pitfall to Avoid

• Never ignore bilirubin elevation—any rise in bilirubin mandates immediate cessation regardless of transaminase levels 6
• Do not continue either medication in patients with decompensated cirrhosis without expert consultation, as altered prescribing practices are necessary 7, 8
• Idiosyncratic drug reactions occur equally in patients with normal or abnormal liver function, so baseline abnormalities alone do not predict hepatotoxicity risk 7, 8